Earlier detection of osteoporosis than ever

LONDON and KUOPIO, Finland, May 12, 2026 /PRNewswire/ -- Boots has launched a new pilot Bone Density Scan Service utilizing Bindex ultrasound technology. With the Bindex device, osteoporosis risk can be detected in a quick assessment available at selected Boots pharmacies. The collaboration helps raise awareness of personal osteoporosis risk earlier and encourages proactive steps before fractures occur. It is also part of a broader shift in healthcare--from hospital to community.

A gradually developing condition is often diagnosed too late - until now

Osteoporosis is often called "a silent condition." According to the NHS, osteoporosis weakens bones, making them fragile and more likely to break, and diagnosis often follows a fracture. In the UK, 3.5 million people are living with osteoporosis, and more than 500,000 fragility fractures occur each year--around one every minute--according to the Royal Osteoporosis Society.

Bone Index Finland Ltd, the company behind Bindex®, enables earlier identification of osteoporosis risk. The pilot brings Bindex's point-of-care bone health technology into a convenient assessment available in familiar community healthcare settings.

"Too often, osteoporosis is recognised only after a fracture has already occurred. This collaboration aims to change that pathway by making bone health assessment more accessible, scalable, and actionable in real-world care settings," said Janne Karjalainen, CEO of Bone Index Finland Ltd. "By bringing point-of-care assessment closer to where people already seek health advice, we can support earlier identification, clearer next steps, and more proactive prevention."

Earlier detection with a proven and portable device

Bindex® is a portable, radiation-free ultrasound device designed for accessible point-of-care bone health assessment. It enables healthcare providers to identify individuals who may benefit from further advice, lifestyle support, or clinical follow-up--all within community healthcare settings.

The Bindex® system has been validated in multiple clinical studies with DXA. It is CE-marked, MHRA-registered, and FDA-cleared. According to the company, more than four million scans have been performed globally, supported by clinical studies across Europe and the US.

Collaboration as part of a broader shift

The collaboration reflects a broader shift in healthcare toward prevention, community-based services, and digital health. In recent public commentary, Karjalainen highlighted the role of Bindex® pulse-echo ultrasonometry in point-of-care osteoporosis screening and fragility fracture prevention, emphasizing the need for earlier risk identification and improved accessibility in real-world settings. Karjalainen also linked Bindex's UK activities to NHS priorities such as moving care from hospital to community and from sickness to prevention.

About Bindex®

Bindex® is a portable, radiation-free pulse-echo ultrasound technology developed by Bone Index Finland Ltd for osteoporosis screening and diagnostics. The device measures cortical bone thickness at the shinbone and calculates a Density Index to help identify individuals at higher risk of osteoporosis.

Media contacts

Bone Index Finland Ltd: info@boneindex.com
Phone: +358 50 448 1696

Photo -
Logo -

View original content:https://www.prnewswire.co.uk/news-releases/bindex-brings-osteoporosis-screening-to-boots-pharmacies-302768418.html

Images

Tags

More Like This

Bone Index Announces Successful Financing Round and Strategic Partnership with Lynx Financial

Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment

AI Innovation for automated Detection and Classification of osteoporotic Fractures of the Spine in CT Scans - ImageBiopsy Lab launches IB Lab FLAMINGO

ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities

Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software

b-rayZ Secures CE Mark for Industry-First Custom AI Technology, Revolutionizing End-to-End Breast Diagnostics

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical